Table 1 Patient demographics and characteristics at baseline
From: Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
Age, years; mean (SD) | 46.8 (10.4) |
Female (%) | 78.1 |
Caucasian (%) | 86.7 |
Years since MS diagnosis; mean (SD) | 10.6 (7.9) |
Number of MS DMTs used prior to natalizumab; mean (SD) | 2.0 (1.1) |
Proportion of patients treated with 1 DMT prior to natalizumab | 35 |
Proportion of patients treated with ≥ 2 DMTs prior to natalizumab | 62 |
SF-12v2 PCS; mean (SE) | 34.2 (0.6) |
SF-12v2 MCS; mean (SE) | 43.2 (0.7) |
Proportion of patients with SF-12v2 PCS ≤ 50a | 91 |
Proportion of patients with SF-12v2 MCS ≤ 50a | 69 |
FS; mean (SD) | 2.6 (1.1)b |
DS; mean (SD) | 2.8 (1.8)c |